By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CytomX Therapeutics, Inc. 

650 Gateway Boulevard
Suite 125
South San Francisco  California  94080-7014  U.S.A.
Phone: 650-515-4987 Fax: 650-351-0353



Company News
CytomX Announces The First Patient Treated In Phase I/II PROCLAIM-072 Trial 2/2/2017 10:34:20 AM
CytomX Announces U.S. FDA Clearance Of Investigational New Drug Application For Phase I/II Clinical Study Of Anti-PD-L1 Probody Therapeutic, CX-072 12/14/2016 6:54:31 AM
CytomX Announces Selection By Bristol-Myers Squibb (BMY) Of First Clinical Candidate Probody From Collaboration 12/13/2016 7:55:08 AM
CytomX Announces Fourth Target Selection By Bristol-Myers Squibb (BMY) Under Strategic Oncology Collaboration 12/5/2016 8:26:05 AM
CytomX Announces Third Quarter 2016 Financial Results And Provides Pipeline Update 11/4/2016 9:58:00 AM
CytomX To Announce Third Quarter 2016 Financial Results 10/27/2016 7:37:23 AM
Deal Spree for AbbVie (ABBV) Continues with $500 Million Cancer Tie-Up with Bay Area's CytomX 4/22/2016 6:16:31 AM
CytomX Added to Russell 2000 Index 12/21/2015 11:49:21 AM
CytomX Selects Probody Drug Conjugate Clinical Candidate, CX-2009, Targeting Highly Expressed Tumor Antigen, CD166 12/11/2015 7:10:00 AM
CytomX To Present At Oppenheimer's 26th Annual Healthcare Conference 12/1/2015 8:44:59 AM